Apheresis Variability Control In Cell Therapy Manufacturing
T cell receptor (TCR)-based treatments, such CAR-T cell therapy, have become a focus of research and could eventually play an important role in standard of care for cancer. Making these treatments — and the processes used to create them — adaptable to many patients remains a key challenge in standardizing immunotherapies, due to inherent and significant source product variability.
Peripheral blood collection with apheresis processing is a preferred method for obtaining patient source material for cell therapies, as it is minimally invasive and results in the collection of a large number of cells. This article contains a collection of resources and information about apheresis products and their characteristics, manner of collection, and processing. Explore our best practices for apheresis collection and obtention of enriched product for cell therapies.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.